Clasado’s Bimuno (B-GOS) demonstrates significant efficacy in the reduction of exercise-induced asthma in Nottingham Trent University clinical study
Clasado Biosciences Limited, the producers and suppliers of Bimuno (B-GOS), a unique patented trans-galactooligosaccharide complex, have announced the publication of results for the latest clinical study using B-GOS.
The human study, conducted by Nottingham Trent University’s School of Science and Technology, demonstrated a significant 40% reduction in the severity of exercise-induced asthma following consumption of B-GOS.
This is the first human study to demonstrate the potential for a prebiotic to be used as an adjunct therapy in exercise induced asthma, and airway inflammation.
The study is published in the British Journal of Nutrition and titled “A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway inflammation.” It reports a substantial reduction in airway narrowing and inflammation in adults with exercise induced asthma following intake of B-GOS for three weeks.
More than five million people have asthma in the UK, and 334 million worldwide. Exercise-induced asthma can affect up to 90% of asthma patients. The Global Asthma Network (GAN) Steering Group estimates from studies in The Global Asthma Report 2014 that the economic cost of asthma to society was $56bn in the US in 2007 and €19.3bn in Europe in 2011. Indirect costs of asthma, especially the negative impact on productivity, are at least as large as the direct costs.
'The finding that B-GOS can reduce exercise induced bronchoconstriction will be of great interest to clinicians and asthma sufferers alike. Although this is early stage work, it raises the prospect that our unique carbohydrate complex could be used as an adjunct to existing asthma therapy. This could potentially benefit millions of sufferers,' said Graham Waters, CEO, Clasado. 'This new study adds to Clasado’s growing portfolio of clinical and preclinical research demonstrating efficacy across a wide variety of different health conditions from metabolic syndrome to anxiety.'
The clinical study is the latest in a 12 year ongoing research programme of preclinical and clinical trials being undertaken by Clasado in collaboration with a range of internationally recognised research institutes. These studies have demonstrated efficacy in a diverse range of health areas including metabolic syndrome immune function, irritable bowel syndrome, stress management and pathogen protection.
'Our study shows that B-GOS could be used as a potential additional therapy for exercise-induced asthma,' said lead researcher Dr Neil Williams, a lecturer in exercise physiology and nutrition at Nottingham Trent University’s School of Science and Technology.
'We are only just starting to understand the role the gut microbiome plays in health and disease — and it is becoming increasingly recognised that microbes living in the gut can have a substantial influence on immune function and allergies, which is likely to be important in airway disease. B-GOS significantly increases the growth and activity of good gut bacteria. This in turn may reduce the inflammatory response of the airways in asthma patients to exercise. Importantly, the level of improvement in lung function that appears after administration of B-GOS is perceivable by the patient and therefore potentially clinically relevant.'